ONCAlert | Upfront Therapy for mRCC

Colorectal Cancer MORE >>

A dose-escalation strategy for giving regorafenib improved the frequency of adverse events while still demonstrating similar efficacy to a standard-dose strategy in patients with metastatic colorectal cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.